TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of Vildagliptin Compared to Placebo in Patients With Type 2 Diabetes and Mild Hyperglycemia
Brief Summary: This study is not being conducted in the United States. Key long-term clinical studies have shown that people with type 2 diabetes should try to achieve overall blood glucose levels as close to normal as possible. The purpose of this study is to assess the safety and effectiveness of vildagliptin, an unapproved drug, compared to placebo in lowering overall blood glucose levels in people with type 2 diabetes who have not been previously treated with drug therapy to lower their blood sugar and whose blood glucose levels are close to normal.


Options:
A: Intervention Type: DRUG; Name: vildagliptin; Assigned to Arm(s): N/A
B: Arm Label: Sitagliptin 100 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Comparator: Sitagliptin, Drug: Comparator: Pioglitazone, Drug: Metformin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Comparator: Placebo, Drug: Comparator: Pioglitazone, Drug: Metformin | Intervention Type: DRUG; Name: Comparator: Sitagliptin; Assigned to Arm(s): Sitagliptin 100 mg | Intervention Type: DRUG; Name: Comparator: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Comparator: Pioglitazone; Assigned to Arm(s): Placebo, Sitagliptin 100 mg | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Placebo, Sitagliptin 100 mg
C: Arm Label: Vildagliptin; Type: EXPERIMENTAL; Interventions: Drug: vildagliptin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Vildagliptin Placebo | Intervention Type: DRUG; Name: vildagliptin; Assigned to Arm(s): Vildagliptin | Intervention Type: DRUG; Name: Vildagliptin Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Vildagliptin 50 mg qd + pioglitazone 45 mg qd; Type: EXPERIMENTAL; Interventions: Drug: Vildagliptin, Drug: pioglitazone | Arm Label: Vildagliptin 50 mg bid + pioglitazone 45 mg qd; Type: EXPERIMENTAL; Interventions: Drug: Vildagliptin, Drug: pioglitazone | Arm Label: Vildagliptin placebo + pioglitazone 45 mg qd; Type: PLACEBO_COMPARATOR; Interventions: Drug: pioglitazone, Drug: Placebo | Intervention Type: DRUG; Name: Vildagliptin; Assigned to Arm(s): Vildagliptin 50 mg bid + pioglitazone 45 mg qd, Vildagliptin 50 mg qd + pioglitazone 45 mg qd | Intervention Type: DRUG; Name: pioglitazone; Assigned to Arm(s): Vildagliptin 50 mg bid + pioglitazone 45 mg qd, Vildagliptin 50 mg qd + pioglitazone 45 mg qd, Vildagliptin placebo + pioglitazone 45 mg qd | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Vildagliptin placebo + pioglitazone 45 mg qd

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Drug Naive Patients With Type 2 Diabetes
Brief Summary: Many people with type 2 diabetes cannot maintain target blood glucose levels when taking a single oral drug. The purpose of this study is to assess the safety and effectiveness of the combination of vildagliptin, an unapproved drug, and pioglitazone in lowering overall blood glucose levels in people with type 2 diabetes who have not previously been treated with drug therapy to lower their blood sugar.


Options:
A: Arm Label: LY2189265 1.5 mg; Type: EXPERIMENTAL; Interventions: Drug: LY2189265, Drug: Metformin, Drug: Glimepiride | Arm Label: LY2189265 0.75 mg; Type: EXPERIMENTAL; Interventions: Drug: LY2189265, Drug: Metformin, Drug: Glimepiride | Arm Label: Insulin Glargine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin Glargine, Drug: Metformin, Drug: Glimepiride | Intervention Type: DRUG; Name: Insulin Glargine; Assigned to Arm(s): Insulin Glargine | Intervention Type: DRUG; Name: LY2189265; Assigned to Arm(s): LY2189265 0.75 mg, LY2189265 1.5 mg | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Insulin Glargine, LY2189265 0.75 mg, LY2189265 1.5 mg | Intervention Type: DRUG; Name: Glimepiride; Assigned to Arm(s): Insulin Glargine, LY2189265 0.75 mg, LY2189265 1.5 mg
B: Arm Label: Vildagliptin; Type: EXPERIMENTAL; Interventions: Drug: vildagliptin | Arm Label: Metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin Comparator | Intervention Type: DRUG; Name: vildagliptin; Assigned to Arm(s): Vildagliptin | Intervention Type: DRUG; Name: Metformin Comparator; Assigned to Arm(s): Metformin
C: Arm Label: 1.5 mg LY2189265; Type: EXPERIMENTAL; Interventions: Drug: LY2189265, Drug: Placebo (oral) | Arm Label: 0.75 mg LY2189265; Type: EXPERIMENTAL; Interventions: Drug: LY2189265, Drug: Placebo (oral) | Arm Label: Metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin, Drug: Placebo (subcutaneous) | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Metformin | Intervention Type: DRUG; Name: LY2189265; Assigned to Arm(s): 0.75 mg LY2189265, 1.5 mg LY2189265 | Intervention Type: DRUG; Name: Placebo (oral); Assigned to Arm(s): 0.75 mg LY2189265, 1.5 mg LY2189265 | Intervention Type: DRUG; Name: Placebo (subcutaneous); Assigned to Arm(s): Metformin
D: Intervention Type: DRUG; Name: vildagliptin; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Drug Naive Patients With Type 2 Diabetes
Brief Summary: Many people with type 2 diabetes cannot maintain target blood glucose levels when taking a single oral drug. The purpose of this study is to assess the safety and effectiveness of the combination of vildagliptin, an unapproved drug, and pioglitazone in lowering overall blood glucose levels in people with type 2 diabetes who have not previously been treated with drug therapy to lower their blood sugar.


Options:
A: Intervention Type: DRUG; Name: vildagliptin; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: vildagliptin; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: vildagliptin; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: vildagliptin; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Aripiprazole in Adolescents With Schizophrenia
Brief Summary: The purpose of this trial is to test the safety and efficacy of aripiprazole in adolescent patients with schizophrenia for a period of at least 6 weeks.


Options:
A: Arm Label: A1; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Arm Label: A2; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Arm Label: A3; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Arm Label: B1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): A1, A2, A3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): B1
B: Arm Label: A1; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Arm Label: A2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): A1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): A2
C: Arm Label: Aripiprazole 10 mg/day Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aripiprazole tablet, 10 mg | Arm Label: Aripiprazole 30 mg/day Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aripiprazole tablet, 30 mg | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo tablet | Intervention Type: DRUG; Name: Aripiprazole tablet, 10 mg; Assigned to Arm(s): Aripiprazole 10 mg/day Group | Intervention Type: DRUG; Name: Aripiprazole tablet, 30 mg; Assigned to Arm(s): Aripiprazole 30 mg/day Group | Intervention Type: DRUG; Name: Placebo tablet; Assigned to Arm(s): Placebo Group
D: Arm Label: Aripiprazole; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): Aripiprazole | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Aripiprazole in Adolescents With Schizophrenia
Brief Summary: The purpose of this trial is to test the safety and efficacy of aripiprazole in adolescent patients with schizophrenia for a period of at least 6 weeks.


Options:
A: Arm Label: Aripiprazole 10 mg/day Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aripiprazole tablet, 10 mg | Arm Label: Aripiprazole 30 mg/day Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aripiprazole tablet, 30 mg | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo tablet | Intervention Type: DRUG; Name: Aripiprazole tablet, 10 mg; Assigned to Arm(s): Aripiprazole 10 mg/day Group | Intervention Type: DRUG; Name: Aripiprazole tablet, 30 mg; Assigned to Arm(s): Aripiprazole 30 mg/day Group | Intervention Type: DRUG; Name: Placebo tablet; Assigned to Arm(s): Placebo Group
B: Intervention Type: DRUG; Name: Quetiapine Fumarate; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Placebo Controlled Study Evaluating the Efficacy and Safety of AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Refractory to Splenectomy
Brief Summary: The purpose of this study is to evaluate the efficacy of AMG 531 in the treatment of thrombocytopenia in subjects with ITP as measured by the platelet response. This study will also evaluate changes in Patient Reported Outcomes and Health Resource Utilization due to treatment with AMG 531.


Options:
A: Arm Label: AMG 531; Type: EXPERIMENTAL; Interventions: Biological: AMG 531 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: BIOLOGICAL; Name: AMG 531; Assigned to Arm(s): AMG 531 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Part A: Romiplostim 0.2 µg/kg; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Arm Label: Part A: Romiplostim 0.5 µg/kg; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Arm Label: Part A: Romiplostim 1.0 µg/kg; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Arm Label: Part A: Romiplostim 3 µg/kg; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Arm Label: Part A: Romiplostim 6 µg/kg; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Arm Label: Part A: Romiplostim 10 µg/kg; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Arm Label: Part B: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Part B: Romiplostim 1.0 µg/kg; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Arm Label: Part B: Romiplostim 3.0 µg/kg; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Arm Label: Part B: Romiplostim 6.0 µg/kg; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Intervention Type: DRUG; Name: Romiplostim; Assigned to Arm(s): Part A: Romiplostim 0.2 µg/kg, Part A: Romiplostim 0.5 µg/kg, Part A: Romiplostim 1.0 µg/kg, Part A: Romiplostim 10 µg/kg, Part A: Romiplostim 3 µg/kg, Part A: Romiplostim 6 µg/kg, Part B: Romiplostim 1.0 µg/kg, Part B: Romiplostim 3.0 µg/kg, Part B: Romiplostim 6.0 µg/kg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Part B: Placebo
C: Arm Label: Observed Subjects; Type: N/A; Interventions: Other: No Intervention for Observational Study | Intervention Type: OTHER; Name: No Intervention for Observational Study; Assigned to Arm(s): Observed Subjects
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: AMG 531; Type: EXPERIMENTAL; Interventions: Biological: AMG 531 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BIOLOGICAL; Name: AMG 531; Assigned to Arm(s): AMG 531

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Placebo Controlled Study Evaluating the Efficacy and Safety of AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Prior to Splenectomy
Brief Summary: The purpose of this study is to evaluate the efficacy of AMG 531 in the treatment of thrombocytopenia in subjects with ITP as measured by the platelet response. This study will also evaluate changes in Patient Reported Outcomes and Health Resource Utilization due to treatment with AMG 531.


Options:
A: Arm Label: AMG 531; Type: EXPERIMENTAL; Interventions: Biological: AMG 531 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: BIOLOGICAL; Name: AMG 531; Assigned to Arm(s): AMG 531 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Treatment arm plus standard of care; Type: EXPERIMENTAL; Interventions: Drug: eltrombopag | Arm Label: placebo plus standard of care; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: eltrombopag; Assigned to Arm(s): Treatment arm plus standard of care | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo plus standard of care
C: Arm Label: Observed Subjects; Type: N/A; Interventions: Other: No Intervention for Observational Study | Intervention Type: OTHER; Name: No Intervention for Observational Study; Assigned to Arm(s): Observed Subjects
D: Arm Label: Romiplostim; Type: EXPERIMENTAL; Interventions: Biological: Romiplostim | Arm Label: Standard of Care; Type: OTHER; Interventions: Drug: Medical Standard of Care for ITP | Intervention Type: DRUG; Name: Medical Standard of Care for ITP; Assigned to Arm(s): Standard of Care | Intervention Type: BIOLOGICAL; Name: Romiplostim; Assigned to Arm(s): Romiplostim

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparing the Effects of an Internet-Based to an Established Dyspnea Self-Management Program on Dyspnea, Exercise Behavior, and Pulmonary Exacerbations in Patients With COPD
Brief Summary: The overall goal of this study is to compare the impact of a new Internet Dyspnea Self-Management Program (eDSMP) with an established face-to-face Dyspnea Self-Management Program (DSMP) in patients with COPD. The primary aim of the study is to test the following two hypotheses: 1. The eDSMP and the DSMP will have comparable improvements in the primary outcomes of shortness of breath (dyspnea) with activities of daily living (ADL), exercise adherence and performance, and pulmonary exacerbations (frequency and duration) at 3 and 6 months. 2. The eDSMP and the DSMP will have comparable improvements in the secondary outcomes of perception of support, self-efficacy for exercise and managing dyspnea, and health resource utilization at 3 and 6 months. This study is a randomized, longitudinal, repeated measures design with measurement times at 0, 3, and 6 months.


Options:
A: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Technology Assisted Case Management; Type: EXPERIMENTAL; Interventions: Behavioral: Technology-Assisted Case Management | Intervention Type: BEHAVIORAL; Name: Technology-Assisted Case Management; Assigned to Arm(s): Technology Assisted Case Management
B: Arm Label: Home Telemonitoring; Type: EXPERIMENTAL; Interventions: Device: Intel Health Guide | Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Intervention Type: DEVICE; Name: Intel Health Guide; Assigned to Arm(s): Home Telemonitoring | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual Care
C: Intervention Type: BEHAVIORAL; Name: Internet-based Dyspnea Self-Management Program; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Face-to-face Dyspnea Self-Management Program; Assigned to Arm(s): N/A
D: N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparing the Effects of an Internet-Based to an Established Dyspnea Self-Management Program on Dyspnea, Exercise Behavior, and Pulmonary Exacerbations in Patients With COPD
Brief Summary: The overall goal of this study is to compare the impact of a new Internet Dyspnea Self-Management Program (eDSMP) with an established face-to-face Dyspnea Self-Management Program (DSMP) in patients with COPD. The primary aim of the study is to test the following two hypotheses: 1. The eDSMP and the DSMP will have comparable improvements in the primary outcomes of shortness of breath (dyspnea) with activities of daily living (ADL), exercise adherence and performance, and pulmonary exacerbations (frequency and duration) at 3 and 6 months. 2. The eDSMP and the DSMP will have comparable improvements in the secondary outcomes of perception of support, self-efficacy for exercise and managing dyspnea, and health resource utilization at 3 and 6 months. This study is a randomized, longitudinal, repeated measures design with measurement times at 0, 3, and 6 months.


Options:
A: Intervention Type: BEHAVIORAL; Name: Internet-based Dyspnea Self-Management Program; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Face-to-face Dyspnea Self-Management Program; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: case management | Arm Label: 2; Type: OTHER; Interventions: Behavioral: usual care | Intervention Type: BEHAVIORAL; Name: case management; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: usual care; Assigned to Arm(s): 2
C: Arm Label: Outlook Intervention; Type: EXPERIMENTAL; Interventions: Other: Life Completion | Arm Label: Attention Control; Type: ACTIVE_COMPARATOR; Interventions: Other: Attention Control | Arm Label: Treatment as Usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Life Completion; Assigned to Arm(s): Outlook Intervention | Intervention Type: OTHER; Name: Attention Control; Assigned to Arm(s): Attention Control
D: Arm Label: ES; Type: ACTIVE_COMPARATOR; Interventions: Device: Electrostimulation | Arm Label: Sham ES; Type: PLACEBO_COMPARATOR; Interventions: Device: Sham stimulation | Intervention Type: DEVICE; Name: Electrostimulation; Assigned to Arm(s): ES | Intervention Type: DEVICE; Name: Sham stimulation; Assigned to Arm(s): Sham ES

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparing the Effects of an Internet-Based to an Established Dyspnea Self-Management Program on Dyspnea, Exercise Behavior, and Pulmonary Exacerbations in Patients With COPD
Brief Summary: The overall goal of this study is to compare the impact of a new Internet Dyspnea Self-Management Program (eDSMP) with an established face-to-face Dyspnea Self-Management Program (DSMP) in patients with COPD. The primary aim of the study is to test the following two hypotheses: 1. The eDSMP and the DSMP will have comparable improvements in the primary outcomes of shortness of breath (dyspnea) with activities of daily living (ADL), exercise adherence and performance, and pulmonary exacerbations (frequency and duration) at 3 and 6 months. 2. The eDSMP and the DSMP will have comparable improvements in the secondary outcomes of perception of support, self-efficacy for exercise and managing dyspnea, and health resource utilization at 3 and 6 months. This study is a randomized, longitudinal, repeated measures design with measurement times at 0, 3, and 6 months.


Options:
A: Arm Label: Intervention- Home Pulmonary Rehabilitation; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention- Home-based Pulmonary Rehabilitation | Arm Label: Control- Choice; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Intervention- Home-based Pulmonary Rehabilitation; Assigned to Arm(s): Intervention- Home Pulmonary Rehabilitation
B: Arm Label: Intervention group "tele-rehabilitation"; Type: EXPERIMENTAL; Interventions: Behavioral: Virtual Autonomous Physiotherapist Agent (VAPA) | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Virtual Autonomous Physiotherapist Agent (VAPA) | Intervention Type: BEHAVIORAL; Name: Virtual Autonomous Physiotherapist Agent (VAPA); Assigned to Arm(s): Control, Intervention group "tele-rehabilitation"
C: Intervention Type: BEHAVIORAL; Name: Internet-based Dyspnea Self-Management Program; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Face-to-face Dyspnea Self-Management Program; Assigned to Arm(s): N/A
D: Arm Label: Home-based pulmonary rehabilitation; Type: EXPERIMENTAL; Interventions: Behavioral: Home-based pulmonary rehabilitation | Arm Label: Hospital-based pulmonary rehabilitation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Hospital-based pulmonary rehabilitation | Intervention Type: BEHAVIORAL; Name: Home-based pulmonary rehabilitation; Assigned to Arm(s): Home-based pulmonary rehabilitation | Intervention Type: BEHAVIORAL; Name: Hospital-based pulmonary rehabilitation; Assigned to Arm(s): Hospital-based pulmonary rehabilitation

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparing the Effects of an Internet-Based to an Established Dyspnea Self-Management Program on Dyspnea, Exercise Behavior, and Pulmonary Exacerbations in Patients With COPD
Brief Summary: The overall goal of this study is to compare the impact of a new Internet Dyspnea Self-Management Program (eDSMP) with an established face-to-face Dyspnea Self-Management Program (DSMP) in patients with COPD. The primary aim of the study is to test the following two hypotheses: 1. The eDSMP and the DSMP will have comparable improvements in the primary outcomes of shortness of breath (dyspnea) with activities of daily living (ADL), exercise adherence and performance, and pulmonary exacerbations (frequency and duration) at 3 and 6 months. 2. The eDSMP and the DSMP will have comparable improvements in the secondary outcomes of perception of support, self-efficacy for exercise and managing dyspnea, and health resource utilization at 3 and 6 months. This study is a randomized, longitudinal, repeated measures design with measurement times at 0, 3, and 6 months.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: case management | Arm Label: 2; Type: OTHER; Interventions: Behavioral: usual care | Intervention Type: BEHAVIORAL; Name: case management; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: usual care; Assigned to Arm(s): 2
B: Intervention Type: BEHAVIORAL; Name: Intermediate care package; Assigned to Arm(s): N/A
C: Intervention Type: BEHAVIORAL; Name: Internet-based Dyspnea Self-Management Program; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Face-to-face Dyspnea Self-Management Program; Assigned to Arm(s): N/A
D: Arm Label: usual care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: care at initiative of the patient (usual GP care) | Arm Label: monitoring controls; Type: EXPERIMENTAL; Interventions: Behavioral: regular practice nurse review (monitoring controls) | Arm Label: self-management; Type: EXPERIMENTAL; Interventions: Behavioral: an integrated self-management education program | Intervention Type: BEHAVIORAL; Name: an integrated self-management education program; Assigned to Arm(s): self-management | Intervention Type: BEHAVIORAL; Name: regular practice nurse review (monitoring controls); Assigned to Arm(s): monitoring controls | Intervention Type: BEHAVIORAL; Name: care at initiative of the patient (usual GP care); Assigned to Arm(s): usual care

Answer: C